Compare Mercadolibre Inc (MELI) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mercadolibre Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Mercadolibre Inc trades at $1,821 (market cap $95.11B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Mercadolibre Inc is far larger — about 97.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Mercadolibre Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mercadolibre Inc for 118 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| MELI | MRVI | |
|---|---|---|
Market Cap | $95.11B | $972.90M |
Volume | 242,115 | 4,325,710 |
Sector | Consumer Cyclical | Health |
52-Week High | $2.36K | $9.00 |
52-Week Low | $1.55K | $2.83 |
Typical Hold Time | 118 Days | 0 Days |
Enterprise Value | $102.76B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MercadoLibre (MELI) trades at $1,839.11, down 2.82% on the day, amid a bullish technical setup and strong analyst support. The stock shows robust revenue growth, with 2025 sales reaching $28.89 billion, though net income margins have softened. Recent news highlights expansion in Brazil, including one-hour delivery and pharmacy services, while its fintech credit portfolio surged 75% in Q2 2026.
Outlook remains positive given dominant Latin American e-commerce and fintech positioning, but risks include macroeconomic pressures in key markets like Argentina and elevated valuation multiples. Wall Street consensus is strongly bullish with a $2,160 price target, though profit trends warrant monitoring for sustained shareholder returns.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
